Review Criteria: Information was gathered by searching PubMed for papers dealing with aromatic L-amino acid decarboxylase activity and the conversion of L-DOPA to dopamine particularly in animal models and human Parkinson's disease studies. Attention was given to papers that reported enhanced conversion of L-DOPA to dopamine following treatment with neuroactive drugs. This information can be used as a model for the design of novel L-DOPA treatment adjuvants to benefit patients with Parkinson's disease. This is a review of a new approach for treating and evaluating new therapies for Parkinson's disease. This is also a summary of the current literature on the topic.
Enhancing Aromatic L-amino Acid Decarboxylase Activity: Implications for L-DOPA Treatment in Parkinson's Disease
Article first published online: 11 NOV 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
CNS Neuroscience & Therapeutics
Volume 14, Issue 4, pages 340–351, Winter 2008
How to Cite
Hadjiconstantinou, M. and Neff, N. H. (2008), Enhancing Aromatic L-amino Acid Decarboxylase Activity: Implications for L-DOPA Treatment in Parkinson's Disease. CNS Neuroscience & Therapeutics, 14: 340–351. doi: 10.1111/j.1755-5949.2008.00058.x
- Issue published online: 11 NOV 2008
- Article first published online: 11 NOV 2008
- Aromatic L-amino acid decarboxylase;
- L-DOPA decarboxylation;
- Neurotransmitter receptors;
- Parkinson's disease;
Aromatic L-amino acid decarboxylase (AAAD) is an essential enzyme for the formation of catecholamines, indolamines, and trace amines. Moreover, it is a required enzyme for converting L-DOPA to dopamine when treating patients with Parkinson's disease (PD). There is now substantial evidence that the activity of AAAD in striatum is regulated by activation and induction, and second messengers play a role. Enzyme activity can be modulated by drugs acting on a number of neurotransmitter receptors including dopamine (D1–4), glutamate (NMDA), serotonin (5-HT1A, 5-HT2A) and nicotinic acetylcholine receptors. Generally, antagonists enhance AAAD activity; while, agonists may diminish it. Enhancement of AAAD activity is functional, as the formation of dopamine from exogenous L-DOPA mirrors activity. Following a lesion of nigrostriatal dopaminergic neurons, AAAD in striatum responds more robustly to pharmacological manipulations, and this is true for the decarboxylation of exogenous L-DOPA as well. We review the evidence for parallel modulation of AAAD activity and L-DOPA decarboxylation and propose that this knowledge can be exploited to optimize the formation of dopamine from exogenous L-DOPA. This information can be used as a blue print for the design of novel L-DOPA treatment adjuvants to benefit patients with PD.